« Return to News | Drug Sponsors

OPKO Health acquires Farmadiet Group Holding

Friday, August 3, 2012 10:38 AM

OPKO Health, a global biopharmaceutical and diagnostics company, has decided to acquire Farmadiet Group Holding, a Spanish company that develops, manufactures and markets pharmaceutical, nutraceutical and veterinary products.

With this acquisition, OPKO establishes a presence in the E.U. through an established regional, integrated specialty pharmaceutical participant. The acquisition also allows OPKO near term product commercialization synergies through introduction of Farmadiet’s products to OPKO’s existing Latin American operations. Farmadiet’s product development pipeline also offers many near-term new product entry opportunities.

"This acquisition is an excellent strategic fit as we expand our global manufacturing, sales and distribution capabilities for a growing range of products,” said Phillip Frost, M.D., chairman and CEO of OPKO. “We anticipate important launches near-term of products from Farmadiet’s rich pipeline. We also expect Farmadiet to market OPKO’s diagnostics and pharmaceutical products as they become available for market and sale.”

Further details of the agreement will be included in OPKO’s 8-K filing with the Securities and Exchange Commission.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.